Our RAMP (Re-engineering Approach with Metabolism Preserved) drug innovation engine enables us to design and develop novel small-molecule product candidates that leverage the clinical experience gained from currently marketed kinase inhibitor drugs that target non-CNS diseases. Using preexisting clinical experience as a template, we pursue the clinically validated kinases as targets to create first-in-class small-molecule kinase inhibitors that have predetermined human safety profiles for the treatment of kinase inhibitor-sensitive CNS diseases.
The RAMP technology enables:
- safety enhancements achieved through chemical modifications that lead to dose reduction, enabling chronic administration with minimized side effects
- preservation of the favorable side-effect profile of the “template” medication, achieved through medicinal chemistry changes to how the drug is metabolized in the body
Using this approach, Inhibikase is advancing a new class of small-molecule CNS drug candidates that target specific protein kinases in the CNS with dramatically enhanced potency and improved safety profiles that may be administered chronically and systemically to patients with infectious or neurodegenerative CNS diseases.
Starting with clinically validated targets, Inhibikase’s approach significantly reduces the risk of developing a new class of kinase inhibitor drugs with enhanced potency and safety that may be administered chronically and systemically for the treatment of CNS diseases.
RAMP Drug Innovation Engine
Inhibikase’s proprietary RAMP medicinal chemistry technology leverages the experience and knowledge generated from validated kinase inhibitor drugs that target non-CNS indications to create novel drugs with enhanced potency and preserved safety profile for the treatment of CNS diseases. The technology generates multiple distinct product candidates from the same clinically validated kinase inhibitor that have the potential to address a range of therapeutic areas using a common kinase targeting strategy.
Inhibikase’s intellectual property includes patents issued or pending as well as know-how related to the composition and broad use of its technologies across all major CNS diseases and all major infection classes. In aggregate, Inhibikase has carved out a broad and deep intellectual property position that enables the development of the company’s internal product pipeline and supports value-creating partnerships with biotechnology and pharmaceutical companies.